Market Valuation: $14 Billion
Ironbound Buy-Side Valuation: $22 Billion
Ironbound Assessment: Ireland based Horizon Therapeutics Public Limited Company, founded in 2005, is a leading high-growth biotech company focused on innovative medicines for rare autoimmune severe inflammatory diseases. Our upside buyout valuation is $22 Billion or 20-times the average sales reportedbetween 2019-2021 and continued double digit sales growth for the foreseeable future. At this valuation, roughly 70% of the acquisition value is Goodwill for the rights to develop and produce TEPEZZA®, their blockbuster thyroid eye disease (TED) medicine. TED is about four-times more prevalent in women than men, affecting roughly 24,000 women in the United States. TEPEZZA® promises a phenomenal growth opportunity; upon FDA approval in 2020 initial sales jumped over 100% from $820 Billion to over $1.6 Billion and accounted for over half of sales in 2021. The $28.3 Billion acquisition by Amgen will further expand thier portfolio of breakaway potential drugs and immediately increase future sales projections by an additional 10% annually – pushing its own $140 Billion valuation even higher.
We are strategy consultants helping Sovereign Wealth Funds optimize investment strategies that leverage stakeholder values.
Note: All blog comments containing hate speech will be deleted.